• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

TxCell - Articles and news items

GED-0301-crohn's-disease

TxCell reacquires full rights to Ovasave from Trizell

Industry news / 3 December 2015 / Victoria White

TxCell has agreed with Trizell to terminate the collaboration, option, development and license agreement concerning TxCell’s lead product Ovasave…

masthercell

MaSTherCell to manufacture TxCell’s lead product Ovasave

Industry news / 29 July 2015 / Victoria White

TxCell and MaSTherCell have signed a Memorandum of Understanding for the manufacturing by MaSTherCell of clinical batches of TxCell’s Ovasave…

txcell

TxCell appoints Stéphane Boissel as Chief Executive Officer and promotes Miguel Forte to Chief Operating Officer

Industry news / 28 April 2015 / Victoria White

TxCell has appointed Stéphane Boissel as CEO. In addition, Dr. Miguel Forte, previously SVP Clinical and Regulatory, has been promoted to COO…

ovasave

TxCell and Trizell amend agreement to accelerate Ovasave development

Industry news / 24 April 2015 / Victoria White

TxCell has announced an amendment to the Ovasave collaboration option, development and license agreement (Ovasave Agreement) with Trizell…

TxCell

TxCell to present at EU Advanced Therapies Investor Day November 13, in London, UK

Industry news / 7 November 2014 / TxCell

TxCell SA announces that Damian Marron, CEO, TxCell, will present at the 2nd Annual EU Advanced Therapies Investor Day in London…

TxCell

TxCell reports revenues for the third quarter of 2014

Industry news / 5 November 2014 / TxCell

TxCell (FR0010127662 – TXCL), a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, today reports its revenues(1) as of September 30, 2014…

Lymphocyte

Clinical trial success for Crohn’s Disease cell therapy

Industry news, News / 30 March 2011 / UK National Stem Cell Network (UKNSCN)

Professor Miguel Forte will describe research into a new cell therapy at the UK National Stem Cell Network annual science meeting…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +